

[NOTICE: This consolidated financial summary is a translation of the Japanese original for reference purposes only, and in the event of any discrepancy, the Japanese original shall prevail.]

Consolidated Financial Summary under Japanese GAAP for the Fiscal Year Ended September 30, 2025

November 6, 2025

Company Name: Amvis Holdings, Inc.	Stock Exchange Listing: Tokyo
Code Number: 7071	URL: https://www.amvis.com/en/
Representative: Keiichi Shibahara, Representative Director and CEO	
Inquiries: Shingo Yamaguchi, Director	TEL: +81-3-6262-5105
General Meeting of Shareholders Date: December 19, 2025	Dividend Payment Date: December 22, 2025
Securities Report Issue Date: December 25, 2025	
Supplementary Information for Financial Statements: Available	
Explanatory Meeting to Be held: Yes	

(Amounts of less than one million yen are truncated)

1. Consolidated Financial Results for the Fiscal Year Ended September 30, 2025

(1) Consolidated Operating Results (% represents the change from the previous fiscal year)

	Net Sales		EBITDA		Operating Profit		Ordinary Profit		Profit Attributable to Owners of Parent	
Fiscal Year Ended	million yen	%	million yen	%	million yen	%	million yen	%	million yen	%
September 30, 2025	49,174	15.8	8,966	(28.2)	6,162	(41.9)	6,343	(39.9)	3,660	(50.8)
September 30, 2024	42,475	32.8	12,480	26.9	10,612	23.0	10,551	23.5	7,438	17.9

Notes

- Comprehensive Income
Fiscal year September 30, 2025: 3,647 million yen / (51.0) %
Fiscal year September 30, 2024: 7,438 million yen / 17.9%
- EBITDA = Operating profit + Depreciation + Amortization of goodwill + Share-based compensation expenses

	Earnings per Share	Diluted Earnings per Share	Return on Equity	Ratio of Ordinary Profit to Total Assets	Ratio of Operating Profit to Net Sales
Fiscal Year Ended	yen	yen	%	%	%
September 30, 2025	37.52	37.51	10.6	8.1	12.5
September 30, 2024	75.86	75.81	24.9	16.6	25.0

Reference: Profit or loss on equity method investments:

Fiscal year ended September 30, 2025: - million yen

Fiscal year ended September 30, 2024: - million yen

(2) Consolidated Financial Position

	Total Assets	Total Net Assets	Shareholders' Equity Ratio	Net Assets per Share
As of	million yen	million yen	%	yen
September 30, 2025	83,947	36,132	43.0	370.46
September 30, 2024	71,799	33,212	46.3	339.39

Reference: Shareholders' equity:

As of September 30, 2025: 36,132 million yen

As of September 30, 2024: 33,212 million yen

(3) Consolidated Cash Flow

	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalents at the end of period
Fiscal Year ended	million yen	million yen	million yen	million yen
September 30, 2025	6,025	(10,427)	6,365	10,833
September 30, 2024	7,484	(16,828)	6,083	8,868

2. Dividends on Common Stock

	Dividends per Share					Total Dividends (annual)	Payout Ratio (consolidated)	Dividends to Net Assets (consolidated)
	1st quarter end	2nd quarter end	3rd quarter end	Fiscal year end	Annual			
Fiscal Year Ended	yen	yen	yen	yen	yen	million yen	%	%
September 30, 2024	—	0.00	—	4.00	4.00	391	5.3	1.3
September 30, 2025	—	0.00	—	4.00	4.00	390	10.7	1.1
Fiscal Year Ending September 30, 2026		0.00		4.00	4.00		18.6	

3. Consolidated Earnings Forecasts for the Fiscal Year Ending September 30, 2026

(% represents the change from the previous fiscal year)

	Net Sales		EBITDA		Operating Profit		Ordinary Profit		Profit Attributable to Owners of Parent		Earnings per Share
	million yen	%	million yen	%	million yen	%	million yen	%	million yen	%	yen
Fiscal Year Ending September 30, 2026	51,700	5.1	7,100	(20.8)	3,800	(38.3)	3,300	(48.0)	2,100	(42.6)	21.53

Notes

1. Significant changes in the scope of consolidation: Yes

Newly included: 1 company

(Company name) Midori

Excluded: None

Notes

For details, please refer to the attachment on page 15 entitled “3. Consolidated Financial Statements and Principal Notes, (5) Notes Regarding Consolidated Financial Statements (Changes in the Scope of Consolidation).”

2. Changes in accounting policies, accounting estimates and restatement of correction

(A) Changes in accounting policies due to revision of accounting standards: Yes

(B) Other changes in accounting policies: No

(C) Changes in accounting estimates: No

(D) Restatement of corrections: No

Notes

For details, please refer to the attachment on page 15 entitled “3. Consolidated Financial Statements and Principal Notes, (5) Notes Regarding Consolidated Financial Statements (Changes in Accounting Policies).”

3. Number of shares outstanding (common shares)

(A) Total shares outstanding including treasury shares

As of September 30, 2025	98,112,000 shares
As of September 30, 2024	98,112,000 shares

(B) Treasury shares

As of September 30, 2025	578,157 shares
As of September 30, 2024	252,856 shares

(C) Average outstanding shares

Fiscal Year Ended September 30, 2025	97,559,825 shares
Fiscal Year Ended September 30, 2024	98,055,417 shares

Reference: Summary of the Non-consolidated Financial Results

1. Non-consolidated Financial Results for the Fiscal Year Ended September 30, 2025

(1) Non-consolidated Operating Results

(% represents the change from the previous fiscal year)

	Operating Revenue		Operating Profit		Ordinary Profit		Net Profit	
Fiscal Year Ended	million yen	%	million yen	%	million yen	%	million yen	%
September 30, 2025	8,248	(12.3)	2,387	(53.5)	2,279	(55.9)	2,142	(58.2)
September 30, 2024	9,403	78.4	5,137	125.3	5,173	131.7	5,125	132.9

	Earnings per Share	Diluted Earnings per Share
Fiscal Year Ended	yen	yen
September 30, 2025	21.97	21.96
September 30, 2024	52.27	52.24

(2) Non-consolidated Financial Position

	Total Assets	Total Net Assets	Shareholders' Equity Ratio	Net Assets per Share
As of	million yen	million yen	%	yen
September 30, 2025	57,783	20,956	36.3	214.86
September 30, 2024	49,324	19,540	39.6	199.68

Reference: Shareholders' equity:

As of September 30, 2025: 20,956 million yen

As of September 30, 2024: 19,540 million yen

This report is exempt from the audit procedures by CPAs or audit firms.

Notes for using earnings forecasts in this report and others

Disclaimer regarding forward-looking information including appropriate use of forecast financial results

This report contains forward-looking statements, such as earnings forecasts, regarding the intent, beliefs and current expectations of Amvis Holdings, Inc. (hereinafter referred to as the "Company") and its management with respect to the expected financial position and results of operations of the Company. Actual performance and results may differ from those forecasts due to various factors.

Table of Contents of Appendix

1. Consolidated Operating Results	5
(1) Overview of Consolidated Operating Results.....	5
(2) Overview of Financial Position	5
(3) Overview of Cash Flows	7
(4) Forecast.....	7
2. Basic Concept Regarding the Selection of Accounting Standards	7
3. Consolidated Financial Statements and Principal Notes	8
(1) Consolidated Balance Sheets	8
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	10
Consolidated Statements of Income.....	10
Consolidated Statements of Comprehensive Income.....	11
(3) Consolidated Statements of Changes in Net Assets	12
(4) Consolidated Statements of Cash Flows	13
(5) Notes Regarding Consolidated Financial Statements	15
(Going Concern Assumption)	15
(Change in Scope of Consolidation or Equity Method).....	15
(Changes in Accounting Policies)	15
(Segment Information)	15
(Per Share Information).....	16
(Significant Subsequent Events)	16

1. Consolidated Operating Results

(1) Overview of Consolidated Operating Results

The Group has set forth the vision of becoming “*the world’s most exciting medical and healthcare company*.” Following the hospice (*Ishinkan*) business, the Group aims to establish its second and third pillars of business and to become a company that will continue to prosper for the next 100 years.

During the current fiscal year, the Group opened 29 new facilities under the *Ishinkan* business (Iwate: 1, Ibaraki: 1, Saitama: 2, Chiba: 1, Tokyo: 5, Kanagawa: 1, Niigata: 1, Toyama: 1, Ishikawa: 1, Gifu: 1, Shizuoka: 1, Aichi: 2, Mie: 1, Hyogo: 3, Tottori: 1, Hiroshima: 1, Kagawa: 1, Ehime: 1, Fukuoka: 1, Oita: 1, Miyazaki: 1), and expanded one existing facility (Shizuoka: 1). Meanwhile, the Group closed one facility (*Ishinkan Hongo*) and transferred the operations of *Ishinkan Himeji* to another operator. Going forward, the Group will continue to implement detailed marketing and development strategies to proactively open new facilities, while also engaging in vigorous sales activities targeting medical institutions and others. Through these initiatives, the Group aims to achieve long-term and sustainable growth.

In recent years, the Group has leveraged the expertise and know-how accumulated through the operation of *Ishinkan* facilities and has fully entered the comprehensive medical support business. During the current consolidated fiscal year, the Group steadily built a track record of providing management support services to medical institutions.

Going forward, the Group will expand its initiatives beyond local and depopulated areas to provide comprehensive management support to a wide range of medical institutions, including general hospitals and community-based hospitals.

The Group will continue to be a hungry challenger, boldly questioning conventional practices and exploring innovative solutions to create essential and fundamental value, while envisioning an ambitious future.

As a result, the operating results for the current consolidated fiscal year are as follows.

[Consolidated Financial Results for the Fiscal Year Ended September 30, 2025]

(Unit: million yen)

	Fiscal Year Ended September 30, 2024	Fiscal Year Ended September 30, 2025	YoY Change	YoY(%)
Net Sales	42,475	49,174	6,699	15.8%
EBITDA	12,480	8,966	(3,513)	(28.2%)
Operating Profit	10,612	6,162	(4,450)	(41.9%)
Ordinary Profit	10,551	6,343	(4,207)	(39.9%)
Profit Attributable to Owners of Parent	7,438	3,660	(3,778)	(50.8%)

(Note) EBITDA = Operating Profit + Depreciation + Amortization of goodwill + Share-based compensation expenses

(2) Overview of Financial Position

(Assets)

Total assets as of September 30, 2025 were 83,947 million yen, an increase of 12,148 million yen from September 30, 2024. This is attributable mainly to increases of 1,964 million yen in cash and deposits due to higher borrowings, and 8,421 million yen in property, plant and equipment and 349 million yen in leasehold and guarantee deposits in line with opening new facilities.

(Liabilities)

Total liabilities as of September 30, 2025 were 47,814 million yen, an increase of 9,227 million yen from September 30, 2024. This is attributable mainly to increases of 7,360 million yen in borrowings and 1,043 million yen in lease obligations in line with opening new facilities, 1,039 million yen in accounts payable - other and accrued expenses due to the business expansion.

(Net assets)

Net assets as of September 30, 2025 amounted to 36,132 million yen, an increase of 2,920 million yen from September 30, 2024. This increase was mainly due to a rise of 3,660 million yen in profit attributable to owners of parent and a decrease of 391 million

yen due to the payment of dividends, resulting in a net increase of 3,268 million yen in retained earnings.

In addition, the acquisition of treasury shares caused an increase of 278 million yen in treasury shares, which was a factor decreasing net assets.

(3) Overview of Cash Flows

Cash and cash equivalents as of September 30, 2025 stood at 10,833 million yen, an increase of 1,964 million yen from September 30, 2024. Cash flows for the period and the factors contributing to increases or decreases in cash flows are described below.

(Cash flows from operating activities)

Net cash provided by operating activities for the fiscal year ended September 30, 2025 was 6,025 million yen, versus 7,484 million yen for the fiscal year ended September 30, 2024. This is attributable mainly to profit before income taxes of 5,685 million yen, depreciation of 2,753 million yen, despite income taxes paid of 3,528 million yen, and an increase in accounts receivable of 731 million yen.

(Cash flows from investing activities)

Net cash used in investing activities for the fiscal year ended September 30, 2025 was 10,427 million yen, versus 16,828 million yen for the fiscal year ended September 30, 2024. This reflected mainly purchase of property, plant and equipment of 10,407 million yen and payments of leasehold and guarantee deposits of 443 million yen in conjunction with the opening of new facilities.

(Cash flows from financing activities)

Net cash provided by financing activities for the fiscal year ended September 30, 2025 was 6,365 million yen, versus 6,083 million yen for the fiscal year ended September 30, 2024. This is attributable mainly to proceeds from short-term borrowings of 4,366 million yen in conjunction with the opening of new facilities and net increase in long-term borrowings of 7,613 million yen, despite repayments of long-term borrowings of 4,639 million yen.

(4) Forecast

The Group's policy is to pursue long-term and sustainable growth by steadily expanding the *Ishinkan* business through the opening of new facilities based on detailed marketing and development strategies, while also conducting vigorous sales activities targeting medical institutions and other related organizations. In the next fiscal year, the Group plans to open nine new facilities, bringing the total number of facilities to 139 (7,232 beds) as of the end of September 2026. In addition to contributions from newly opened facilities, the Group expects a moderate recovery in occupancy rates at existing facilities. However, taking into account uncertainties such as the impact of the revision of medical service fees scheduled for FY2026 and the increase in personnel and other expenses, the Group has formulated its plan on a conservative basis. Furthermore, the Group will continue to strengthen its initiatives in the comprehensive medical support business, including collaboration with medical institutions and community-based efforts to address social issues such as regional disparities in medical access. The Group has decided to emphasize EBITDA as a key performance indicator, aiming to eliminate accounting distortions and focus on the returns from strategic investments.

Based on these premises, the Group forecasts net sales of 51,700 million yen, EBITDA of 7,100 million yen, operating profit of 3,800 million yen, ordinary profit of 3,300 million yen, and profit attributable to owners of parent of 2,100 million yen for the next fiscal year. The above forecasts are based on information available at the time of publication and are subject to uncertainties. However, actual results may differ materially from these forecasts due to changes in business conditions and other factors.

2. Basic Concept Regarding the Selection of Accounting Standards

To facilitate comparison with other companies in the same industry in Japan, the Group employs Japanese GAAP as its accounting standard.

3. Consolidated Financial Statements and Principal Notes

(1) Consolidated Balance Sheets

	(Unit: million yen)	
	As of September 30, 2024	As of September 30, 2025
Assets		
Current assets		
Cash and deposits	8,868	10,833
Accounts receivable	8,452	9,191
Inventories	23	30
Other	1,168	1,855
Allowance for doubtful accounts	(62)	(171)
Total current assets	18,451	21,738
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	35,009	43,979
Machinery, equipment and vehicles, net	3	4
Tools, furniture and fixtures, net	43	202
Leased assets, net	6,976	7,914
Land	2,382	2,471
Construction in progress	4,328	2,592
Total property, plant and equipment	48,743	57,165
Intangible assets		
Other	73	185
Total intangible assets	73	185
Investments and other assets		
Leasehold and guarantee deposits	3,220	3,570
Deferred tax assets	759	851
Other	550	436
Total investments and other assets	4,531	4,857
Total non-current assets	53,348	62,208
Total assets	71,799	83,947

(Unit: million yen)

	As of September 30, 2024	As of September 30, 2025
Liabilities		
Current liabilities		
Accounts payable	122	149
Short-Term borrowings	3,333	7,699
Current portion of long-term borrowings	4,150	4,763
Lease obligations	176	202
Accounts payable - other and accrued expenses	2,709	3,748
Income taxes payable	1,884	433
Provision for bonuses	1,022	1,310
Other	406	1,137
Total current liabilities	13,805	19,444
Non-current liabilities		
Long-term borrowings	16,896	19,277
Lease obligations	7,193	8,210
Provision for litigation losses	-	11
Asset retirement obligations	548	639
Net defined benefit liability	29	66
Other	113	164
Total non-current liabilities	24,781	28,369
Total liabilities	38,586	47,814
Net assets		
Shareholders' equity		
Share capital	65	66
Capital surplus	11,701	11,641
Retained earnings	21,918	25,187
Treasury shares	(472)	(750)
Total shareholders' equity	33,212	36,145
Accumulated other comprehensive income		
Remeasurements of defined benefit plans	(0)	(12)
Total accumulated other comprehensive income	(0)	(12)
Total net assets	33,212	36,132
Total liabilities and net assets	71,799	83,947

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

[Consolidated Statements of Income]

(Unit: million yen)

	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025
Net sales	42,475	49,174
Cost of sales	25,415	34,385
Gross profit	17,059	14,789
Selling, general and administrative expenses	6,447	8,626
Operating profit	10,612	6,162
Non-operating income		
Subsidy income	239	500
Gain on sale of non-current assets	0	-
Compensation income	37	-
Gain on sale of investments	-	149
Miscellaneous income	46	111
Total non-operating income	324	761
Non-operating expenses		
Interest expenses	359	563
Amortization of share issuance cost	6	-
Miscellaneous loss	19	16
Total non-operating expenses	385	580
Ordinary profit	10,551	6,343
Extraordinary Income		
Insurance claim income	-	50
Total Extraordinary Income	-	50
Extraordinary losses		
Special investigation expenses	-	650
Provision for loss on litigation	-	11
Others	-	46
Total extraordinary losses	-	708
Profit before income taxes	10,551	5,685
Income taxes	3,281	2,077
Income taxes-deferred	(168)	(51)
Total income taxes	3,112	2,025
Profit	7,438	3,660
Profit attributable to non-controlling interests	-	-
Profit attributable to owners of parent	7,438	3,660

[Consolidated Statements of Comprehensive Income]

(Unit: million yen)

	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025
Profit	7,438	3,660
Other comprehensive income		
Remeasurements of defined benefit plans	0	(12)
Total other comprehensive income	0	(12)
Comprehensive income	7,438	3,647
(Details)		
Attributable to owners of parent	7,438	3,647
Attributable to non-controlling interests	-	-

(3) Consolidated Statements of Changes in Net Assets

Fiscal year ended September 30, 2024

(Unit: million yen)

	Shareholder's Equity					Accumulated Other Comprehensive Income		Total Net Assets
	Share Capital	Capital Surplus	Retained Earnings	Treasury Shares	Total Shareholders' Equity	Remeasurements of Defined Benefit Plans	Total Accumulated Other Comprehensive Income	
Balance at the beginning of current period	57	11,693	14,774	(1)	26,523	(0)	(0)	26,523
Changes during the period								
Dividends from surplus			(294)		(294)			(294)
Issuance of new shares	7	7			15			15
Profit attributable to owners of parent			7,438		7,438			7,438
Acquisition of treasury shares				(470)	(470)			(470)
Restricted stock					-			-
Net changes of items other than shareholders' equity						0	0	0
Total changes during the period	7	7	7,144	(470)	6,688	0	0	6,689
Balance at the end of current period	65	11,701	21,918	(472)	33,212	(0)	(0)	33,212

Fiscal year ended September 30, 2025

(Unit: million yen)

	Shareholder's Equity					Accumulated Other Comprehensive Income		Total Net Assets
	Share Capital	Capital Surplus	Retained Earnings	Treasury Shares	Total Shareholders' Equity	Remeasurements of Defined Benefit Plans	Total Accumulated Other Comprehensive Income	
Balance at the beginning of current period	65	11,701	21,918	(472)	33,212	(0)	(0)	33,212
Changes during the period								
Dividends from surplus			(391)		(391)			(391)
Issuance of new shares	1	1			3			3
Profit attributable to owners of parent			3,660		3,660			3,660
Acquisition of treasury shares				(389)	(389)			(389)
Restricted stock		(61)		110	49			49
Net changes of items other than shareholders' equity						(12)	(12)	(12)
Total changes during the period	1	(59)	3,268	(278)	2,932	(12)	(12)	2,920
Balance at the end of current period	66	11,641	25,187	(750)	36,145	(12)	(12)	36,132

(4) Consolidated Statements of Cash Flows

(Unit: million yen)

	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025
Cash flows from operating activities		
Profit before income taxes	10,551	5,685
Loss (Gain) on transfer of business	-	46
Insurance claim income	-	(50)
Loss (Gain) on sale of investments	-	(149)
Depreciation	1,848	2,753
Amortization of goodwill	-	17
Increase (decrease) in provision for bonuses	268	288
Increase (decrease) in allowance for doubtful accounts	8	109
Interest income	(2)	(15)
Interest expenses	359	563
Subsidy income	(239)	(500)
Compensation income	(37)	-
Decrease (increase) in accounts receivable	(1,967)	(731)
Decrease (increase) in inventories	(8)	(6)
Decrease (increase) in other assets	(559)	(479)
Increase (decrease) in accounts payable	(15)	26
Increase (decrease) in accounts payable - other and accrued expenses	148	1,163
Increase (decrease) in other liabilities	(16)	825
Other, net	8	12
Subtotal	10,346	9,561
Interest and dividends received	0	20
Interest paid	(340)	(578)
Proceeds from subsidy	239	500
Proceeds from compensation	37	-
Proceeds from insurance income	-	50
Income taxes paid	(2,798)	(3,528)
Net cash provided by (used in) operating activities	7,484	6,025
Cash flows from investing activities		
Purchase of property, plant and equipment	(15,982)	(10,407)
Purchase of intangible assets	(23)	(17)
Proceeds from sale of businesses	-	360
Payments for acquisition of business	-	(115)
Payments of leasehold and guarantee deposits	(849)	(443)
Proceeds from refund of leasehold and guarantee deposits	12	40
Other, net	14	156
Net cash provided by (used in) investing activities	(16,828)	(10,427)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	1,066	4,366
Proceeds from long-term borrowings	9,174	7,613
Repayments of long-term borrowings	(3,254)	(4,639)
Repayments of lease obligations	(150)	(191)
Proceeds from issuance of shares	15	-
Dividends paid	(294)	(391)

Purchase of treasury shares	(473)	(390)
Net cash provided by (used in) financing activities	6,083	6,365
Net increase (decrease) in cash and cash equivalents	(3,259)	1,964
Cash and cash equivalents at the beginning of period	12,128	8,868
Cash and cash equivalents at the end of period	8,868	10,833

(5) Notes Regarding Consolidated Financial Statements

(Going Concern Assumption)

Not applicable.

(Change in Scope of Consolidation or Equity Method)

(Significant change in scope of consolidation)

During the fiscal year under review, the Company included Midori Co., Ltd. in the scope of consolidation as it acquired all shares of the company.

(Changes in Accounting Policies)

(Application of Accounting Standards for Corporate, Inhabitant and Enterprise Taxes)

The Accounting Standard for Corporate, Inhabitant and Enterprise Taxes (ASBJ Statement No. 27, issued on October 28, 2022; hereinafter referred to as the "Revised Accounting Standard 2022") and other related standards have been applied from the beginning of the fiscal year ended September 30, 2025.

The amendment to the categories in which current income taxes should be recorded (taxes on other comprehensive income) follows the transitional treatment prescribed in paragraph 20-3 of the Revised Accounting Standard 2022 and paragraph 65-2 of the Revised Implementation Guidance on Tax Effect Accounting (ASBJ Guidance No. 28, issued on October 28, 2022). This change in accounting policies has no material impact on the consolidated financial statements for the fiscal year.

With respect to the amendment related to the revised accounting treatment for consolidated financial statements when gains or losses on the sale of shares in subsidiaries arising from intra-group transactions were deferred for tax purposes, the Revised Implementation Guidance 2022 has been applied from the beginning of the fiscal year ended September 30, 2025. This change in accounting policies was applied retrospectively, and accordingly, the consolidated financial statements for the previous fiscal year have been restated. These changes have no material impact on the consolidated financial statements for the current fiscal year.

(Segment Information)

Segment information is omitted because the Group operates in a single business segment, the *Ishinkan* Business.

(Per Share Information)

	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025
Net assets per share	339.39 yen	370.46 yen
Earnings per share	75.86 yen	37.52 yen
Diluted earnings per share	75.81 yen	37.51 yen

Notes

1. The basis for calculating earnings per share and diluted earnings per share is as follows.

Item	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025
Earnings per share		
Profit attributable to owners of parent (million yen)	7,438	3,660
Profit not attributable to common shareholders (million yen)	—	—
Profit attributable to owners of parent attributable to common shareholders (million yen)	7,438	3,660
Average number of common shares outstanding during the period (shares)	98,055,417	97,559,825
Diluted earnings per share		
Adjustment to profit attributable to owners of parent (million yen)	—	—
Increase in number of common shares (shares)	57,415	13,661
(Number of stock acquisition rights included in the increase) (shares)	(57,415)	(13,661)
Outline of latent shares not included in the calculation of diluted earnings per share due to the absence of dilutive effect	—	—

2. The basis for calculating net assets per share is as follows.

Item	As of September 30, 2024	As of September 30, 2025
Total net assets (million yen)	33,212	36,132
Amount to be deducted from total net assets (million yen)	—	—
Net assets pertaining to common stock at the end of the period (million yen)	33,212	36,132
Number of shares of common stock used for the calculation of net assets per share at the end of the period (shares)	97,859,144	97,533,843

(Significant Subsequent Events)

Not applicable.